Jefferies reiterates Legend Biotech stock rating on Carvykti sales

Jefferies reiterated a Buy on Legend Biotech (LEGN) with a $69 price target while the stock trades at $19.41, implying material upside; the firm forecasted Carvykti worldwide net sales of ~$2.9B (2026) and introduced 2028 estimates. Legend reported LTM revenue of $909M (+75% YoY) and Q4 2025 EPS of $0.01 (in line), though Q4 revenue missed slightly at $306M vs $310.71M consensus. Jefferies expects the franchise to reach breakeven in 2025 driven by adoption and manufacturing scale-up, and the company plans in vivo CAR-T human data in H2 2026.

Analysis

Commercial momentum in a recently growing cell-therapy franchise creates a predictable bottleneck: viral vector and cell-processing capacity will be the binding constraint before additional patient demand is the limiter. That shifts margin expansion from price realization to throughput improvements — winners will be those that secure multi-year CDMO slots or internalize high-yield manufacturing processes, and losers will be small hospitals and outpatient centers that can’t operationalize complex infusion pathways quickly.

The principal tail risks are binary clinical/regulatory events and payer pushback on net price in the face of unclear long-term durability. Expect meaningful volatility around durability signals and quarterly adoption metrics over the next 6–24 months; a single safety/regulatory headline or an outcomes-based rebate negotiation can erase a large chunk of headline multiples within days.

On positioning, the market has likely front-loaded optimism into a small-cap commercialization story, raising sensitivity to execution slippage. That creates asymmetric trade opportunities: own optionality to the commercial upside but hedge against headline risk via either put protection or cross-asset pairs (CDMO equities, broad biotech short). Across horizons, prioritize instruments and sizing that cap downside from a sudden rerating while preserving upside to multi-year adoption and manufacturing scale benefits.

Key Decisions for Investors

• Go long LEGN equity (size 2–4% of risk budget); average in on 10–20% pullbacks; horizon 12–24 months. Risk/reward: aim for 2x–3x upside if adoption scales, with downside capped by buying 12-month protective puts to limit drawdown to ~50%.
• Buy LEGN 18–24 month OTM call spread (buy longer-dated 25–35% OTM calls, sell higher OTM calls to fund). Timeframe 12–30 months. Rationale: asymmetric upside to commercialization/scale; capped cost reduces theta drag versus straight calls.
• Pair trade: long LEGN (core) / short XBI (equal notional) for 6–12 months to isolate franchise execution from broad biotech beta. Risk/reward: reduces market-direction risk; residual is execution/durability exposure.
• Long CDMO exposure — TMO or CTLT — sized 3–5% of portfolio, horizon 12–36 months. Risk/reward: benefits from persistent manufacturing tightness and secular re-rating; downside is a sector-wide demand downgrade or capacity build-out that eases pricing.
• Tactical: avoid selling short into upcoming commercial cadence; instead sell near-term implied vol (weeklies around earnings) only if delta-hedged and with stops — premium selling can be lucrative given recurring headline windows but has high tail risk from binary readouts.